
==== Front
World J Surg Oncol
World J Surg Oncol
World Journal of Surgical Oncology
1477-7819
BioMed Central London

39245733
3519
10.1186/s12957-024-03519-x
Research
A novel nomogram based on the number of positive lymph nodes can predict the overall survival of patients with pancreatic head cancer after radical surgery
You Ke
Lei Kai
Wang Xingxing
Hu Run
Zhang Huizhi
Xu Jie
Liu Zuojin 300376@hospital.cqmu.edu.cn

https://ror.org/00r67fz39 grid.412461.4 Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400000 China
9 9 2024
9 9 2024
2024
22 24123 5 2024
1 9 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Background

This study aimed to construct a novel nomogram based on the number of positive lymph nodes to predict the overall survival of patients with pancreatic head cancer after radical surgery.

Materials and methods

2271 and 973 patients in the SEER Database were included in the development set and validation set, respectively. The primary clinical endpoint was OS (overall survival). Univariate and multivariate Cox regression analyses were used to screen independent risk factors of OS, and then independent risk factors were used to construct a novel nomogram. The C-index, calibration curves, and decision analysis curves were used to evaluate the predictive power of the nomogram in the development and validation sets.

Results

After multivariate Cox regression analysis, the independent risk factors for OS included age, tumor extent, chemotherapy, tumor size, LN (lymph nodes) examined, and LN positive. A nomogram was constructed by using independent risk factors for OS. The C-index of the nomogram for OS was 0.652 [(95% confidence interval (CI): 0.639–0.666)] and 0.661 (95%CI: 0.641–0.680) in the development and validation sets, respectively. The calibration curves and decision analysis curves proved that the nomogram had good predictive ability.

Conclusions

The nomogram based on the number of positive LN can effectively predict the overall survival of patients with pancreatic head cancer after surgery.

Keywords

Lymph node
Nomogram
Overall survival (OS)
Pancreatic head cancer
SEER database
http://dx.doi.org/10.13039/501100001809 National Natural Science Foundation of China 82070678 issue-copyright-statement© BioMed Central Ltd., part of Springer Nature 2024
==== Body
pmcIntroduction

Pancreatic ductal adenocarcinoma (PDAC) is a malignant tumor with a poor prognosis, with a 5-year survival rate of less than 10% [1, 2]. And with the increase of incidence, it will rise to the second leading cause of cancer death in the future [3]. Pancreatic cancer has the characteristics of early metastasis and rapid progression, so many patients with pancreatic head cancer are diagnosed at an advanced stage and have no chance of radical surgery [4]. Patients with early pancreatic head cancer have the opportunity of radical surgery, and the surgical method of pancreatic head cancer is pancreaticoduodenectomy (PD) [5]. When patients with pancreatic head cancer undergo radical surgery, lymph node dissection is an important issue, because if some early metastatic LN are not dissected, the prognosis of patients will be affected [6]. Therefore, the extent of intraoperative lymph node dissection and postoperative lymph node positivity will affect the prognosis of patients [7, 8]. To improve the prognosis of patients with pancreatic head cancer, many studies have investigated the extent of lymph node dissection in PD. The Heidelberg Triangle proposed by Heidelberg University has become a hot topic in pancreatic surgery [9, 10].

However, whether the number of positive LN is related to the survival of patients has not been proven. This study aimed to explore the effect of the number of positive LN on the prognosis of patients and to construct a novel nomogram based on the number of positive LN to predict the overall survival of patients with pancreatic head cancer after radical surgery.

Materials and methods

Data source and patient selection

The data of the patients in this study were obtained from the SEER database. The SEER database was a cancer repository established by the National Cancer Institute and contained data on cancer diagnosis, treatment, and survival for approximately 30% of the population in the United States. Inclusion criteria for patients in the study included: (1) was diagnosed with pancreatic head cancer between 2000 and 2015; (2) had undergone radical resection with lymphadenectomy; (3) postoperative pathology showed pancreatic ductal adenocarcinoma. The exclusion criteria for this study were as follows: (1) absence of key variables, such as the number of LN examined and the number of positive LN; (2) incomplete surgical information, including resection of the primary site and dissection of regional LN; (3) incomplete survival data. Included patients were randomly assigned 7:3 to the development and validation sets.

Data description

The clinical baseline data of the patients in this study included age, sex, tumor extent, AJCC (the American Joint Committee on Cancer) stage, AJCC T, AJCC N, AJCC M, LN scope SUR (surgery), chemotherapy, tumor size, LN examined, LN positive, survival status, and OS. The TNM stage included in this study was based on the AJCC sixth edition. Survival data included vital status at the cut-off date of follow-up and survival months. The primary clinical endpoint was OS, defined as the time from diagnosis to death, or from diagnosis to the end of follow-up if the status was still alive.

Statistical analysis

Clinical data were extracted by using the client-server model of SEER*Stat 8.4.3. All statistical analyses in this study were performed by using SPSS 26.0 software and R software version 4.2.3. Continuous numerical variables in baseline data that did not follow a normal distribution were described with the use of median and IQR (interquartile range). Categorical variables were described by using counts and percentages. Continuous numerical variables between the two sets were compared by using the Mann-Whitney U test. Categorical variables between the two sets were compared by using the chi-square test. Univariate and multivariate Cox regression analyses were used to screen independent risk factors for OS. Independent risk factors were then used to construct a novel nomogram. The predictive performance of the nomogram was evaluated by calculating the C-index. Calibration curves for 1 -, 3 -, and 5-year OS were generated to observe the difference between the predicted and actual survival rates in the development and validation sets. The clinical benefit of the model was observed by comparing the decision analysis curves between the nomogram and conventional AJCC TNM stage. During the statistical analysis, P-value < 0.05 was considered statistically significant.

Results

Clinical characteristics of the included patients

A total of 3244 eligible patients were included in this study. According to randomization in a 7:3 ratio, 2271 and 973 patients were included in the development and validation sets, respectively. Clinical baseline data for patients in the development and validation sets are shown in Table 1. There were statistical differences in age, tumor size, and LN examined between the two sets. Most patients in the development (94.5%) and validation (95.2%) sets had 4 or more lymph node dissection during surgery. The median number of LN examined and LN positive in the development set was 14 (9–21) and 1 (0–4), respectively. And the median number of LN examined and LN positive in the validation set was 16 (11–21) and 2 (0–4), respectively. The median OS of patients in the development set was 21 (11–45) months, and the median OS of patients in the validation set was 22 (11–45) months. There was no statistical difference between the two sets for comparing the median OS ((p-value = 0.165).

Table 1 General characteristics of development set and validation set

Variables	Development set(n = 2271)	Validation set
(n = 973)	P value	
Age	<65	894(39.4%)	442(45.4%)	0.001	
≥ 65	1377(60.6%)	531(54.6%)	
Sex	Male	1183(52.1%)	498(51.2%)	0.635	
Female	1088(47.9%)	475(48.8%)	
Tumor

Extent

	Local	195(8.6%)	83(8.5%)	0.361	
Region	1915(84.3%)	807(82.9%)	
Distant	161(7.1%)	83(8.5%)	
AJCC Stage	I	195(8.6%)	83(8.5%)	0.064	
II	1922(84.6%)	799(82.1%)	
III	76(3.3%)	50(5.1%)	
IV	78(3.4%)	41(4.2%)	
AJCC T	1	119(5.2%)	61(6.3%)	0.077	
2	267(11.8%)	110(11.3%)	
3	1803(79.4%)	750(77.1%)	
4	82(3.6%)	52(5.3%)	
AJCC N	0	716(31.5%)	281(28.9%)	0.134	
1	1555(68.5%)	692(71.1%)	
AJCC M	0	2193(96.6%)	932(95.8%)	0.279	
1	78(3.4%)	41(4.2%)	
LN scope SUR	1 to 3	126(5.5%)	47(4.8%)	0.404	
4 or more	2145(94.5%)	926(95.2%)	
Chemotherapy	No	636(28.0%)	248(25.5%)	0.140	
Yes	1635(72.0%)	725(74.5%)	
Tumor Size (mm)	30(25–40)	30(23–40)	0.039	
LN examined	14(9–21)	16(11–21)	<0.001	
LN positive	1(0–4)	2(0–4)	0.434	
Status	Alive	257(11.3%)	131(13.5%)	0.084	
Dead	2014(88.7%)	842(86.5%)	
OS (months)	21(11–45)	22(11–45)	0.165	
AJCC, the American Joint Committee on Cancer; LN, lymph nodes; SUR, surgery; OS, overall survival

Table 2 Univariate and multivariate analysis of os in development set

Variables	Univariate analysis	Multivariate analysis	
HR (95%CI)	P value	HR (95%CI)	P value	
Age (≥ 65)	1.272

(1.162,1.392)

	<0.001	1.180

(1.076,1.294)

	<0.001	
Sex(Male)	1.068

(0.978,1.165)

	0.142			
Tumor Extent	Region	1.801

(1.519,2.135)

	<0.001	1.925

(1.612,2.299)

	<0.001	
Distant	2.804

(2.230,3.525)

	2.898

(2.291,3.666)

	
LN scope SUR

(4 or more)

	0.878

(0.728,1.059)

	0.173			
Chemotherapy (Yes)	0.610

(0.554,0.672)

	<0.001	0.554

(0.501,0.613)

	<0.001	
Tumor Size (mm)	1.008

(1.005,1.010)

	<0.001	1.005

(1.003,1.008)

	<0.001	
LN examined	0.993

(0.989,0.998)

	0.004	0.986

(0.981,0.991)

	<0.001	
LN positive	1.056

(1.044,1.068)

	<0.001	1.061

(1.048,1.075)

	<0.001	
OS, overall survival; HR, hazard ratio; CI, confidence interval; LN, lymph nodes; SUR, surgery

The construction of the nomogram

The AJCC TNM stage was variable for comparison in this study, so Cox regression analysis was not performed for the AJCC TNM stage. As shown in Fig. 1 and Table 2, after univariate and multivariate Cox regression analyses in the development set, independent risk factors for OS included age (HR = 1.180; 95%CI: 1.076, 1.294; p < 0.001), tumor extent [Region (HR = 1.925; 95%CI: 1.612, 2.299); Distant (HR = 2.898; 95%CI: 2.291, 3.666); p < 0.001], chemotherapy (HR = 0.554; 95%CI: 0.501, 0.613; p < 0.001), tumor size (HR = 1.005; 95%CI: 1.003, 1.008; p < 0.001), LN examined (HR = 0.986; 95%CI: 0.981, 0.991; p < 0.001), and LN positive (HR = 1.061; 95%CI: 1.048, 1.075; p < 0.001). These independent risk factors were used to construct a novel nomogram to predict 1-year OS, 3-year OS, and 5-year OS. The novel nomogram is shown in Fig. 2.

Fig. 1 Multivariate Cox regression analysis of LN positive and other clinical characteristics in the Development set. HR, hazard ratio; CI, confidence interval; LN, lymph nodes

Fig. 2 A novel nomogram was constructed combining LN positive with other independent risk factors of patients with pancreatic head cancer undergoing radical surgery to predict OS. LN, lymph nodes; OS, overall survival

Assessment of the predictive performance

The C-index of this nomogram for OS in the development set and validation set is 0.652 [95% confidence interval (CI): 0.639–0.666)] and 0.661 (95%CI: 0.641–0.680), respectively. The C-index indicates that the nomogram has good predictive ability. As shown in Fig. 3, the calibration curves for 1-year OS, 3-year OS, and 5-year OS in the development and validation sets are close to the reference line. This means that the predicted survival rates of the nomogram are close to the actual survival rates.

Fig. 3 Calibration curves for the nomogram predicting 1-year, 3-year, and 5-year survival of patients in the Development set (A) and the Validation set (B). OS, overall survival

To assess the clinical utility of the nomogram, decision analysis curves are used to compare the net benefit and clinical utility of the nomogram with the conventional AJCC TNM stage. As shown in Fig. 4, the decision analysis curves for 1-year OS, 3-year OS, and 5-year OS in both the development and validation sets show that the constructed nomogram has a larger area than the conventional AJCC TNM stage. This indicates that the nomogram constructed in this study can provide more clinical benefit than the conventional AJCC TNM stage.

Fig. 4 The decision curves evaluate the 1-, 3-, and 5-year clinical benefit of the nomogram and compare the clinical benefit between the nomogram and conventional AJCC TNM stage in the Development (A-C) and Validation (D-F) set. LN, lymph nodes; AJCC, the American Joint Committee on Cancer

Discussion

LN is an important prognostic factor for patients with pancreatic head cancer, which affects postoperative pathological stage and adjuvant therapy [11]. Positive postoperative lymph node is an independent risk factor for the prognosis of patients with pancreatic head cancer [12, 13]. In the AJCC TNM stage, lymph node positivity determines the N stage. In the eighth edition of the AJCC TNM stage, the number of LN has further become the criterion for reference to the N stage [7, 14]. However, due to the anatomy of patients, the experience and technology of operators, neoadjuvant chemotherapy, and the extent of lymph node dissection, the number of LN examined after radical surgery is small in some patients, so the number of positive LN may be inaccurate or even negative. The ratio of the number of positive LN to the number of examined LN in this case does not represent the true level of the lymph node condition of patients with pancreatic head cancer. In this study, the number of examined LN and the number of positive LN were respectively used as variables to explore their relationship with the overall survival of patients with pancreatic head cancer after surgery and a novel nomogram was constructed based on the number of positive LN to predict the overall survival of patients with pancreatic head cancer after radical surgery.

Factors found to be associated with prognosis in this study included age, tumor extent, chemotherapy, tumor size, LN examined, and LN positive. Age is not a contraindication for surgery in patients with pancreatic head cancer [15, 16]. However, elderly patients may have more underlying diseases and poor nutritional status, which may lead to fatal complications and affect the survival of patients [17]. Early pancreatic head cancer is resectable, with a high R0 resection rate, no regional lymph node metastasis and distant metastasis, and a good prognosis [18, 19]. Vascular invasion, regional lymph node metastasis, and even distant lymph node or organ metastasis in pancreatic head cancer indicate that the tumor is in the borderline resectable or advanced stage, which may indicate a high degree of malignancy, strong invasion, and poor prognosis [20]. For pancreatic cancer, a malignant tumor with poor biological behavior, the role of systemic chemotherapy is very important. The role of chemotherapy includes reducing tumor volume, reducing tumor burden, eliminating micrometastases, and thereby reducing postoperative recurrence and metastasis. Many studies have shown that both preoperative neoadjuvant therapy and postoperative adjuvant therapy have a great impact on the prognosis of patients with pancreatic cancer [21–23]. Tumor size represents the tumor burden, which can determine the tumor stage, and even affect the treatment and surgical method of patients with pancreatic head cancer. A larger tumor size may indicate a poor prognosis [24, 25]. Studies have found that even small tumor size is associated with poor prognosis once positive LN are present [26]. This study found that the number of examined LN was also an independent risk factor for the prognosis of patients, and more examined LN were associated with a good prognosis. More LN removed means that more potential metastases are eliminated, and the chance of achieving micro-level radical resection is greater, which can be the reason for the better prognosis [27, 28]. Positive LN determines the advanced stage in patients with pancreatic head cancer. As in existing studies, the presence of positive LN indicates a poor prognosis for the patient [12, 14, 29].

In this study, a novel nomogram was constructed based on the number of positive LN combined with other independent risk factors to predict the overall survival of patients with pancreatic head cancer after radical surgery. Age, tumor extent, chemotherapy, tumor size, LN examined, and LN positive are variables that are readily available in the clinic. This indicates that the nomogram constructed in this study is simple and can be promoted in other institutions. Through the verification of the C-index and calibration curves, it can be proved that the nomogram has good predictive ability. To further evaluate its performance, the decision analysis curves of the nomogram and conventional AJCC TNM stage were compared in this study. Figure 4 shows that this nomogram has greater clinical utility. This indicates that the nomogram is effective and practical.

However, this study has some limitations. First of all, this study is a retrospective database study, and there is a lack of multicenter, prospective studies to verify the results. Secondly, the data of this study came from a database, and some important prognostic variables were difficult to obtain, such as liver function, nutritional status, chemotherapy regimen, and other information about patients. They could not be included in the model and could not further improve the predictive power of the model.

Conclusion

In conclusion, this study demonstrated that the number of LN examined and positive LN after radical surgery was closely related to OS in patients with pancreatic head cancer. The nomogram based on the number of positive LN can effectively predict the OS of patients with pancreatic head cancer after radical surgery.

Author contributions

All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by Ke You, Kai Lei, Xingxing Wang, Run Hu, Huizhi Zhang, Jie Xu, and Zuojin Liu. The first draft of the manuscript was written by Ke You and Kai Lei, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Funding

This work was supported by the National Natural Science Foundation of China (No.82070678).

Data availability

No datasets were generated or analysed during the current study.

Declarations

Ethics statement

According to the Office for Human Research Protection, the study involved data from non-human subjects, and because of its openness and non-identifying nature, they were investigated through the US Department of Health and Human Services. Written informed consent from the patients/participants was not required to participate in this study. This study was reviewed and approved by the Ethics Committee of the Second Affiliated Hospital of Chongqing Medical University. This study complied with the Declaration of Helsinki.

Conflict of interest

All authors declare no conflict of interest.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Siegel RL, Statistics C et al. 2021. CA Cancer J Clin, 2021. 71(1): pp. 7–33.10.3322/caac.21654
2. Rahib L Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States Cancer Res 2014 74 11 2913 21 10.1158/0008-5472.CAN-14-0155 24840647
Rahib L, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913–21. 10.1158/0008-5472.Can-14-0155.24840647 10.1158/0008-5472.CAN-14-0155
3. Rahib L Estimated projection of US Cancer incidence and death to 2040 JAMA Netw Open 2021 4 4 e 10.1001/jamanetworkopen.2021.4708
Rahib L, et al. Estimated projection of US Cancer incidence and death to 2040. JAMA Netw Open. 2021;4(4):e. 10.1001/jamanetworkopen.2021.4708.10.1001/jamanetworkopen.2021.4708
4. Mizrahi JD Pancreatic cancer Lancet 2020 395 10242 2008 20 10.1016/S0140-6736(20)30974-0 32593337
Mizrahi JD, et al. Pancreatic cancer. Lancet. 2020;395(10242):2008–20. 10.1016/s0140-6736(20)30974-0.32593337 10.1016/S0140-6736(20)30974-0
5. Schneider M Technical advances in surgery for pancreatic cancer Br J Surg 2021 108 7 777 85 10.1093/bjs/znab133 34046668
Schneider M, et al. Technical advances in surgery for pancreatic cancer. Br J Surg. 2021;108(7):777–85. 10.1093/bjs/znab133.34046668 10.1093/bjs/znab133
6. Tanaka K, et al. Appropriate Lymph Node Dissection sites for Cancer in the body and tail of the pancreas: a Multicenter Retrospective Study. Cancers (Basel). 2022;14(18). 10.3390/cancers14184409.
7. Chun YS Pawlik TM Vauthey JN 8th Edition of the AJCC Cancer staging Manual: pancreas and hepatobiliary cancers Ann Surg Oncol 2018 25 4 845 7 10.1245/s10434-017-6025-x 28752469
Chun YS, Pawlik TM, Vauthey JN. 8th Edition of the AJCC Cancer staging Manual: pancreas and hepatobiliary cancers. Ann Surg Oncol. 2018;25(4):845–7. 10.1245/s10434-017-6025-x.28752469 10.1245/s10434-017-6025-x
8. Warschkow R Role of lymphadenectomy, adjuvant chemotherapy, and treatment at high-volume centers in patients with resected pancreatic cancer-a distinct view on lymph node yield Langenbecks Arch Surg 2020 405 1 43 54 10.1007/s00423-020-01859-2 32040705
Warschkow R, et al. Role of lymphadenectomy, adjuvant chemotherapy, and treatment at high-volume centers in patients with resected pancreatic cancer-a distinct view on lymph node yield. Langenbecks Arch Surg. 2020;405(1):43–54. 10.1007/s00423-020-01859-2.32040705 10.1007/s00423-020-01859-2
9. Klotz R The TRIANGLE operation for pancreatic head and body cancers: early postoperative outcomes HPB (Oxford) 2022 24 3 332 41 10.1016/j.hpb.2021.06.432 34294523
Klotz R, et al. The TRIANGLE operation for pancreatic head and body cancers: early postoperative outcomes. HPB (Oxford). 2022;24(3):332–41. 10.1016/j.hpb.2021.06.432.34294523 10.1016/j.hpb.2021.06.432
10. Lin Q Standard pancreatoduodenectomy versus extended pancreatoduodenectomy with modified retroperitoneal nerve resection in patients with pancreatic head cancer: a multicenter randomized controlled trial Cancer Commun (Lond) 2023 43 2 257 75 10.1002/cac2.12399 36579790
Lin Q, et al. Standard pancreatoduodenectomy versus extended pancreatoduodenectomy with modified retroperitoneal nerve resection in patients with pancreatic head cancer: a multicenter randomized controlled trial. Cancer Commun (Lond). 2023;43(2):257–75. 10.1002/cac2.12399.36579790 10.1002/cac2.12399
11. Fukuda Y Prognostic impact of nodal statuses in patients with pancreatic ductal adenocarcinoma Pancreatology 2017 17 2 279 84 10.1016/j.pan.2017.01.003 28122676
Fukuda Y, et al. Prognostic impact of nodal statuses in patients with pancreatic ductal adenocarcinoma. Pancreatology. 2017;17(2):279–84. 10.1016/j.pan.2017.01.003.28122676 10.1016/j.pan.2017.01.003
12. Liu ZQ Effect of the number of positive LN and lymph node ratio on prognosis of patients after resection of pancreatic adenocarcinoma Hepatobiliary Pancreat Dis Int 2014 13 6 634 41 10.1016/S1499-3872(14)60264-2 25475867
Liu ZQ, et al. Effect of the number of positive LN and lymph node ratio on prognosis of patients after resection of pancreatic adenocarcinoma. Hepatobiliary Pancreat Dis Int. 2014;13(6):634–41. 10.1016/s1499-3872(14)60264-2.25475867 10.1016/S1499-3872(14)60264-2
13. Fischer LK The number and ratio of positive LN affect pancreatic cancer patient survival after neoadjuvant therapy and pancreaticoduodenectomy Histopathology 2016 68 2 210 20 10.1111/his.12732 25945396
Fischer LK, et al. The number and ratio of positive LN affect pancreatic cancer patient survival after neoadjuvant therapy and pancreaticoduodenectomy. Histopathology. 2016;68(2):210–20. 10.1111/his.12732.25945396 10.1111/his.12732
14. Tarantino I Staging of pancreatic cancer based on the number of positive LN Br J Surg 2017 104 5 608 18 10.1002/bjs.10472 28195303
Tarantino I, et al. Staging of pancreatic cancer based on the number of positive LN. Br J Surg. 2017;104(5):608–18. 10.1002/bjs.10472.28195303 10.1002/bjs.10472
15. van der Heijde N The role of older age and obesity in minimally invasive and open pancreatic surgery: a systematic review and meta-analysis Pancreatology 2020 20 6 1234 42 10.1016/j.pan.2020.06.013 32782197
van der Heijde N, et al. The role of older age and obesity in minimally invasive and open pancreatic surgery: a systematic review and meta-analysis. Pancreatology. 2020;20(6):1234–42. 10.1016/j.pan.2020.06.013.32782197 10.1016/j.pan.2020.06.013
16. Ikenaga N Risks and benefits of pancreaticoduodenectomy in patients aged 80 years and over Langenbecks Arch Surg 2023 408 1 108 10.1007/s00423-023-02843-2 36847904
Ikenaga N, et al. Risks and benefits of pancreaticoduodenectomy in patients aged 80 years and over. Langenbecks Arch Surg. 2023;408(1):108. 10.1007/s00423-023-02843-2.36847904 10.1007/s00423-023-02843-2
17. Maeda S Impact of resection margin status on survival in pancreatic cancer patients after neoadjuvant treatment and pancreatoduodenectomy Surgery 2020 167 5 803 11 10.1016/j.surg.2019.12.008 31992444
Maeda S, et al. Impact of resection margin status on survival in pancreatic cancer patients after neoadjuvant treatment and pancreatoduodenectomy. Surgery. 2020;167(5):803–11. 10.1016/j.surg.2019.12.008.31992444 10.1016/j.surg.2019.12.008
18. Zhang XP A novel online calculator to predict early recurrence and long-term survival of patients with resectable pancreatic ductal adenocarcinoma after pancreaticoduodenectomy: a multicenter study Int J Surg 2022 106 106891 10.1016/j.ijsu.2022.106891 36165934
Zhang XP, et al. A novel online calculator to predict early recurrence and long-term survival of patients with resectable pancreatic ductal adenocarcinoma after pancreaticoduodenectomy: a multicenter study. Int J Surg. 2022;106:106891. 10.1016/j.ijsu.2022.106891.36165934 10.1016/j.ijsu.2022.106891
19. Watson MD The treatment sequence may matter in patients undergoing pancreatoduodenectomy for early stage pancreatic cancer in the era of modern chemotherapy Am J Surg 2021 222 1 159 66 10.1016/j.amjsurg.2020.10.030 33121658
Watson MD, et al. The treatment sequence may matter in patients undergoing pancreatoduodenectomy for early stage pancreatic cancer in the era of modern chemotherapy. Am J Surg. 2021;222(1):159–66. 10.1016/j.amjsurg.2020.10.030.33121658 10.1016/j.amjsurg.2020.10.030
20. Cai J Advances in the epidemiology of pancreatic cancer: Trends, risk factors, screening, and prognosis Cancer Lett 2021 520 1 11 10.1016/j.canlet.2021.06.027 34216688
Cai J, et al. Advances in the epidemiology of pancreatic cancer: Trends, risk factors, screening, and prognosis. Cancer Lett. 2021;520:1–11. 10.1016/j.canlet.2021.06.027.34216688 10.1016/j.canlet.2021.06.027
21. Versteijne E Preoperative Chemoradiotherapy Versus Immediate surgery for Resectable and Borderline Resectable Pancreatic Cancer: results of the Dutch Randomized Phase III PREOPANC Trial J Clin Oncol 2020 38 16 1763 73 10.1200/jco.19.02274 32105518
Versteijne E, et al. Preoperative Chemoradiotherapy Versus Immediate surgery for Resectable and Borderline Resectable Pancreatic Cancer: results of the Dutch Randomized Phase III PREOPANC Trial. J Clin Oncol. 2020;38(16):1763–73. 10.1200/jco.19.02274.32105518 10.1200/jco.19.02274
22. Barnes CA Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery Surgery 2019 166 3 277 85 10.1016/j.surg.2019.05.010 31272811
Barnes CA, et al. Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery. Surgery. 2019;166(3):277–85. 10.1016/j.surg.2019.05.010.31272811 10.1016/j.surg.2019.05.010
23. Fogel EL A Multidisciplinary Approach to Pancreas Cancer in 2016: a review Am J Gastroenterol 2017 112 4 537 54 10.1038/ajg.2016.610 28139655
Fogel EL, et al. A Multidisciplinary Approach to Pancreas Cancer in 2016: a review. Am J Gastroenterol. 2017;112(4):537–54. 10.1038/ajg.2016.610.28139655 10.1038/ajg.2016.610
24. Wei D Clinicopathological correlation of radiologic measurement of post-therapy tumor size and tumor volume for pancreatic ductal adenocarcinoma Pancreatology 2021 21 1 200 7 10.1016/j.pan.2020.11.003 33221151
Wei D, et al. Clinicopathological correlation of radiologic measurement of post-therapy tumor size and tumor volume for pancreatic ductal adenocarcinoma. Pancreatology. 2021;21(1):200–7. 10.1016/j.pan.2020.11.003.33221151 10.1016/j.pan.2020.11.003
25. Marchegiani G Does size Matter in Pancreatic Cancer? Reappraisal of Tumour Dimension as a predictor of Outcome beyond the TNM Ann Surg 2017 266 1 142 8 10.1097/SLA.0000000000001837 27322188
Marchegiani G, et al. Does size Matter in Pancreatic Cancer? Reappraisal of Tumour Dimension as a predictor of Outcome beyond the TNM. Ann Surg. 2017;266(1):142–8. 10.1097/sla.0000000000001837.27322188 10.1097/SLA.0000000000001837
26. Muralidhar V Association between very small Tumor size and decreased overall survival in node-positive pancreatic Cancer Ann Surg Oncol 2018 25 13 4027 34 10.1245/s10434-018-6832-8 30298331
Muralidhar V, et al. Association between very small Tumor size and decreased overall survival in node-positive pancreatic Cancer. Ann Surg Oncol. 2018;25(13):4027–34. 10.1245/s10434-018-6832-8.30298331 10.1245/s10434-018-6832-8
27. Valsangkar NP N0/N1, PNL, or LNR? The effect of lymph node number on accurate survival prediction in pancreatic ductal adenocarcinoma J Gastrointest Surg 2013 17 2 257 66 10.1007/s11605-012-1974-7 23229885
Valsangkar NP, et al. N0/N1, PNL, or LNR? The effect of lymph node number on accurate survival prediction in pancreatic ductal adenocarcinoma. J Gastrointest Surg. 2013;17(2):257–66. 10.1007/s11605-012-1974-7.23229885 10.1007/s11605-012-1974-7
28. Komo T Prognostic impact of Para-aortic Lymph Node Micrometastasis in Pancreatic Ductal Adenocarcinoma Ann Surg Oncol 2016 23 6 2019 27 10.1245/s10434-016-5120-8 26856722
Komo T, et al. Prognostic impact of Para-aortic Lymph Node Micrometastasis in Pancreatic Ductal Adenocarcinoma. Ann Surg Oncol. 2016;23(6):2019–27. 10.1245/s10434-016-5120-8.26856722 10.1245/s10434-016-5120-8
29. Paiella S The prognostic impact of para-aortic lymph node metastasis in pancreatic cancer: a systematic review and meta-analysis Eur J Surg Oncol 2016 42 5 616 24 10.1016/j.ejso.2016.02.003 26916137
Paiella S, et al. The prognostic impact of para-aortic lymph node metastasis in pancreatic cancer: a systematic review and meta-analysis. Eur J Surg Oncol. 2016;42(5):616–24. 10.1016/j.ejso.2016.02.003.26916137 10.1016/j.ejso.2016.02.003
